久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Inching toward first-in-class new drugs

By Liu Zhihua | China Daily | Updated: 2020-12-07 09:28
Share
Share - WeChat
[Photo/IC]

When I started reporting on healthcare around 10 year ago, domestic drugs for cancer treatment were often seen as being less effective than foreign medicine.

Since investing in new drug development does not produce instant or even near-term returns and hence is regarded as risky, domestic pharmaceutical companies tended to produce low-end generics, preferring not to develop innovative or original drugs even when there was high demand.

There were thousands of such small or medium-sized firms that focused on generics, active pharmaceutical ingredients and traditional Chinese medicine. However, regulatory reform starting in 2015 proved to be a game-changer.

In August that year, the State Council, China's Cabinet, released a document on reforming the review and approval system for drugs and medical devices, to promote a structural reform of the pharmaceutical industry with an emphasis on drug efficacy, safety and quality.

Over the years, regulators focused on measures that encourage innovation, especially research and development of new drugs in line with global developments, or as per urgent clinical demand, and also to speed up clinical trial registration and new drug reviews, in order to enhance domestic generics and help bring down drug prices.

In 2017, China became a full member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, an organization that standardizes global drug regulations.

As a result, overseas investment in China's healthcare industry and the number of products launched in the China market by multinational companies have been growing. More importantly, domestic pharmaceutical companies also started to gain increasing presence in both domestic and international markets, especially in the biotech sector.

With the domestic market exerting the pressure of demand for high-quality products, local pharmaceutical companies now invest more in innovation and R&D to make high-end generics and innovative drugs. Some of them have been able to conduct world-class R&D of cutting-edge treatments, such as PD-1/PD-L1 inhibitors, anti-CD47 monoclonal antibodies, and other revolutionary cancer therapeutics.

Although none of those drugs are first-in-class, some have the potential to be best-in-class. And thanks to the increasing number of high-quality homegrown drugs, as well as reforms in healthcare system and supportive policies for drug procurement and reimbursement, drug prices have been brought down drastically.

Official data showed there were three rounds of volume-based drug procedure programs so far, which helped cut the average price of 112 drugs by generic name by 54 percent, saving 53.9 billion yuan ($8.2 billion) in medical costs for patients. Increasing digital capacity is another aspect of innovation in China's pharmaceutical industry. Digital giants and other technology players have been creating solutions that can better serve patients as well as meet the needs of physicians.

All this has led to a surge in investments flowing into the industry, as the country's ongoing reforms have been unleashing the potential of the domestic market.

However, despite the local companies' emphasis on increasing R&D capacities, they are still followers of truly breakthrough innovations; they still need to build up innovation capacities and enhance manufacturing technologies to develop and produce first-in-class drugs.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产精品极品美女自在线看免费一区二区 | 久久日本三级韩国三级 | 中文字幕视频网站 | 久久黄网站| 精品一区二区久久久久久久网站 | 美国一级毛片片aa成人 | 伊人青| 亚洲精品国产精品精 | 久久精品久久精品 | 国产亚洲精品国看不卡 | 欧产日产国产精品精品 | 精品丝袜国产自在线拍亚洲 | 欧美激情精品久久久久久久久久 | 另类视频欧美 | 国产精品视频久久久久 | 九九免费视频 | 日韩一区二区三区视频在线观看 | 免费一级毛片在线播放不收费 | 亚洲欧美手机在线观看 | 国产成人亚洲日本精品 | 好湿好紧好痛a级是免费视频 | 亚洲高清在线观看视频 | 成年美女黄网站小视频 | 欧美精品18videos性欧美 | 免费看国产精品久久久久 | 亚洲欧美日韩国产精品26u | 日本高清不卡在线观看 | 国产高清精品在线 | 99国产精品免费视频观看 | 日韩欧美在线视频一区二区 | 日本免费人成黄页网观看视频 | 久草国产在线播放 | 久久丁香 | 理论视频在线观看 | 成人免费在线网站 | 国产成人高清精品免费5388密 | 国产精品免费观看视频 | 国产精品美女一区二区三区 | 天天操夜夜噜 | 久久这里一区二区精品 | 欧美精品成人一区二区视频一 |